Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. is a joint venture company headquartered in Gurgaon, India. The firm develops and researches vaccines. It was founded in 2009. Raman Rao is the CEO, in this role since 2020.\nThe company says this about itself: Hilleman Laboratories was established as an equal joint venture by MSD and Wellcome Trust in 2009, headquartered in New Delhi, India. Hilleman Laboratories is a global vaccine R&D organization committed to developing high impact, affordable vaccines for low- and middle- income countries. Our translational research focuses on creating safe, low-cost vaccines and innovative delivery technologies that are highly effective and can be easily incorporated into immunization programs. Hilleman Lab’s focus is on transforming ideas into products and technologies through translational R&D and by building partnerships with global stakeholders and vaccine manufacturers.

Sanofi Pasteur SA develops, manufactures, and supplies vaccines in France and internationally. The company provides vaccines for bacterial and viral diseases, including pertussis, diphtheria, typhoid fever, poliomyelitis, influenza, and mumps. It has production sites in France, the United States, Canada, China, Thailand, and Argentina. The company was formerly known as Aventis Pasteur S.A. and changed its name to Sanofi Pasteur SA in 2004. The company was founded in 1990 and is headquartered in Lyon, France. The company is headquartered in Lyon, France. Sanofi Pasteur SA operates as a subsidiary of Sanofi-Aventis.

Baxter Healthcare SA engages in the development, production, and sale of healthcare systems and products. It also acquires and manages participations in pharmaceutical-chemical firms. The company was founded on December 7, 2000 and is headquartered in Glattpark, Switzerland.

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company operates through three segments: BioScience, Medication Delivery, and Renal. - The BioScience segment manufactures recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products and technologies used in adult stem-cell therapies; and vaccines. - The Medication Delivery segment manufactures intravenous solutions and administration sets; premixed drugs and drug-reconstitution systems; pre-filled vials and syringes for injectable drugs, intravenous nutrition products; infusion pumps; and inhalation anesthetics. This segment also offers products and services related to pharmacy compounding, drug formulation, and packaging technologies. - The Renal segment provides products to treat end-stage renal disease and irreversible kidney failure. This segment also offers solutions and other products for peritoneal dialysis, a home-based therapy and product for hemodialysis, which is conducted in a hospital or clinic. Baxter International Inc. has collaborations with HHD LLC, DEKA Products Limited Partnership, and DEKA Research and Development Corp. for the development of a home hemodialysis machine. It markets its products to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, clinical and medical research laboratories, and patients at home under physician supervision. The company was founded in 1931 and is headquartered in Deerfield, Illinois.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Baxalta GmbH, a subsidiary of Takeda Pharmaceutical Co., Ltd., is a Swiss company located in Glattpark that manufactures and wholesales pharmaceutical products. It was founded in 2000. Julie So-Young Kim is currently the CEO of the firm.

Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL.

UCSF Benioff Children's Hospital Oakland provides healthcare services. It offers child life program, family outreach clinics, hand and microsurgery, parent infant programs, pastoral care, neurosurgery, injury prevention programs and respiratory care services. The company was founded by Bertha Wright in 1912 and is headquartered in Oakland, CA.

Chongqing Zhiren Biotechnology Co., Ltd., established on 2004-04-26, Business scope includes licensed projects:wholesale:Chemical raw materials and their preparations,Antibiotic raw materials and their preparations,biochemical drug,Chinese patent medicine,Biological product,road freight transport,Import and export agency,Drug import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:biotechnology development,application(Excludes projects that require pre-approval or licensing as required by laws and regulations),computer software development,application,Sales:office equipment,Instrumentation,Daily necessities,hardware,AC,Chemical Products(Free of chemical hazards),car parts,motorcycle parts(without engine),sales agent,Science popularization service,Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion,General Cargo Warehousing Services(Does not contain hazardous chemicals and other items that require approval)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Beijing Zhifei Green Bamboo Bio-Pharmaceutical Co., Ltd., established on 2003-10-08, The scope of business includes the production of vaccines;Dedicated transport of goods(Refrigerated)(The road transport business license is valid until2024year08moon19day);Biological product,medicine,Diagnostic reagents,Technology development of medical devices,technology transfer,Technical Training,Technical Services;Biotechnology Information Consulting;Sales of laboratory immunological reagents,laboratory apparatus;Import and export,Technology Import and Export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

The J. Craig Venter Institute is a world leader in genomic research. It was formed in October 2006 through the merger of several affiliated and legacy organizations — The Institute for Genomic Research (TIGR) and The Center for the Advancement of Genomics (TCAG), The J. Craig Venter Science Foundation, The Joint Technology Center, and the Institute for Biological Energy Alternatives (IBEA). Today all these organizations have become one large multidisciplinary genomic-focused organization. With more than 400 scientists and staff, more than 250,000 square feet of laboratory space, and locations in Rockville, Maryland and San Diego, California. For more than two decades Dr. J. Craig Venter and his research teams have been pioneers in genomic research. The revolution began in 1991 when at the National Institutes of Health Dr. Venter and his team developed expressed sequence tags (ESTs), a new technique to rapidly discover genes. Dr. Venter and his colleagues then started a new kind of not for profit research institute, The Institute for Genomic Research (TIGR). With the freedom to pursue any number of exciting avenues in the burgeoning field of genomics, the team decided to use their new computing and computational tools, as well as new DNA sequencing technology, to sequence the first free living organism, Haemophilus influenzae in 1995. With this advance, the floodgates of genomics were opened. TIGR went on to sequence and analyze more than 50 microbial genomes. Dr. Venter and some from his team moved into mammalian genomics and sequenced some of the most important model organisms including the fruit fly, mouse and rat. The world’s attention was perhaps most keenly focused on the sequencing and analysis of one genome — the human — which was published in 2001 by Dr. Venter and his team at Celera Genomics. In the past three years teams have been engaged in some of the most fruitful and exciting research in the biological sciences. We’ve recently published the first diploid human genome and the initial results of our global ocean sampling expedition which uncovered more than six million new genes and thousands of new protein families from organisms found in sea water. Teams have also sequenced the microbial flora found in human environments such as the vagina, oral cavity and human gut. We’re making steady progress in our quest to create a synthetic chromosome and organism having successfully transformed one species of bacteria into another. We’ve also sequenced a variety of important infectious disease agents such as the mosquito species, Aedes aegypti, and we are working to understand the evolution of several viral genomes such as influenza and coronavirus in our quest to help alleviate the scourge of infectious disease around the world.

The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of Research Institutes publicly funded by the federal and the state governments of Germany. Additionally, the Max Planck Society and its Institutes receive third party funding from public and private contributions and from the European Union. The world leading organization is named in honor of its former president, theoretical physicist Max Planck. The 86 Institutes and Research Facilities of the Max Planck Society (as of 2020) conduct basic research in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 24,000 permanent employees, including 15,000 scientists, and around 5,000 non-tenured scientists and guests. As of December 31, 2018, the proportion of female employees was 44.4 percent. The Max Planck Society (with its 86 Max Planck Institutes) has a world-leading reputation as a science and technology research organization, with more than 33 Nobel Prizes awarded to its scientists, and is widely regarded as one of the foremost basic research organizations in the world.

USAMRMC